Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
June 26, 2026
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
June 25, 2026
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
May 6, 2026
Nuvation Bio to Participate in Upcoming Investor Conferences
May 5, 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 4, 2026
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
April 27, 2026
←
Previous Page
1
2